Xuelin Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xuelin Li has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Meizi Zhou
Questrom School of Business, Boston University, Boston, Massachusetts 02215
2 shared publications - Richard T. Thakor
University of Minnesota - Carlson School of Management
2 shared publications - Colin Ward1 shared publication
Fangyuan Yu
1 shared publication- Gordon Burtch
Questrom School of Business, Boston University, Boston, Massachusetts 02215
1 shared publication - Joshua L. Krieger
Harvard Business School
1 shared publication
Latest Publications
- 10 August 2026
- Published by Institute for Operations Research and the Management Sciences (INFORMS) in Management Science
The Impact of Manipulated Clinical Decision Support Algorithm on Opioid Prescribing Decision
We document that interactions with manipulated clinical decision support (CDS) systems can induce not only short-term, but also long-term changes in physicians’ opioid prescribing behavior. Physicians in our sample adopted electronic health record software from a list of federally certified vendors in 2011. Between 2016 and Spring 2019, one vendor secretly embedded a biased CDS function designed to promote extended-release opioid sales. Affected physicians not only increased opioid claims relative to the control group during the treatment window, but also maintained a higher propensity to prescribe opioids, even after the biased function was removed. This long-term behavioral change persisted even after affected physicians moved to new locations, changed their affiliations, or faced stricter state-level opioid regulations. Increasing physician awareness helped mitigate this impact. Using machine-learning algorithms, we estimate that decision-making distortion accounts for approximately 54% of the treatment effects in a physician decision model with dynamic learning. This paper was accepted by Hemant Bhargava, information systems. Supplemental Material: The online appendix and data files are available at https://doi.org/10.1287/mnsc.2024.07930 .
- 10 August 2026
- Published by Institute for Operations Research and the Management Sciences (INFORMS) in Management Science
The Impact of Manipulated Clinical Decision Support Algorithm on Opioid Prescribing Decision
We document that interactions with manipulated clinical decision support (CDS) systems can induce not only short-term, but also long-term changes in physicians’ opioid prescribing behavior. Physicians in our sample adopted electronic health record software from a list of federally certified vendors in 2011. Between 2016 and Spring 2019, one vendor secretly embedded a biased CDS function designed to promote extended-release opioid sales. Affected physicians not only increased opioid claims relative to the control group during the treatment window, but also maintained a higher propensity to prescribe opioids, even after the biased function was removed. This long-term behavioral change persisted even after affected physicians moved to new locations, changed their affiliations, or faced stricter state-level opioid regulations. Increasing physician awareness helped mitigate this impact. Using machine-learning algorithms, we estimate that decision-making distortion accounts for approximately 54% of the treatment effects in a physician decision model with dynamic learning. This paper was accepted by Hemant Bhargava, information systems. Supplemental Material: The online appendix and data files are available at https://doi.org/10.1287/mnsc.2024.07930 .
- 1 May 2025
- Published by Elsevier in Journal of Economic Theory
- Vol. 226
Dynamic information design in an entry game
- 1 May 2025
- Published by Elsevier in Journal of Economic Theory
- Vol. 226
Dynamic information design in an entry game
- 1 September 2024
- Published by Institute for Operations Research and the Management Sciences (INFORMS) in Information Systems Research
- Vol. 35 (3) , 1092-1113
Healthcare Across Boundaries: Urban-Rural Differences in the Consequences of Telehealth Adoption
We study the impacts of telehealth adoption on geographic competition among urban and rural healthcare providers. We consider a quasinatural experiment: states’ entry into the Interstate Medical Licensure Compact, wherein the entry events facilitate healthcare providers to adopt telehealth technology. By analyzing a representative sample of providers, we first establish the Compact entry shock’s validity and its positive effect on the supply of medical services. We then report evidence that there are service and payment shifts from rural providers to urban providers (i.e., urban providers are more likely to benefit from the Compact entry financially). Relying on patients’ telehealth reimbursement claim data, we observe two mechanisms contributing to the revenue redistribution: the substitution and gateway effects of telehealth. Finally, we show that telehealth readiness and service quality moderate the impact of telehealth adoption. These findings speak to both potentially positive and negative consequences for welfare.
- 1 September 2024
- Published by Institute for Operations Research and the Management Sciences (INFORMS) in Information Systems Research
- Vol. 35 (3) , 1092-1113
Healthcare Across Boundaries: Urban-Rural Differences in the Consequences of Telehealth Adoption
We study the impacts of telehealth adoption on geographic competition among urban and rural healthcare providers. We consider a quasinatural experiment: states’ entry into the Interstate Medical Licensure Compact, wherein the entry events facilitate healthcare providers to adopt telehealth technology. By analyzing a representative sample of providers, we first establish the Compact entry shock’s validity and its positive effect on the supply of medical services. We then report evidence that there are service and payment shifts from rural providers to urban providers (i.e., urban providers are more likely to benefit from the Compact entry financially). Relying on patients’ telehealth reimbursement claim data, we observe two mechanisms contributing to the revenue redistribution: the substitution and gateway effects of telehealth. Finally, we show that telehealth readiness and service quality moderate the impact of telehealth adoption. These findings speak to both potentially positive and negative consequences for welfare.
- 6 June 2024
- Published by Oxford University Press (OUP) in The Review of Financial Studies
- Vol. 37 (9) , 2817-2854
Financial Effects of Remote Product Delivery: Evidence from Hospitals
We study financial effects of remote product delivery in the healthcare industry. Exploiting staggered law adoption for identification, we find that telehealth provision redistributes hospital operations and access to capital away from rural communities. As urban telehealth providers acquire rural patients, rural hospitals experience decreased revenue and profit, credit rating downgrades, increased cost of capital, and ultimately risk of closure. Although telehealth reduces travel costs, some communities lose access to acute care. Overall, we conclude that remote healthcare services have financial consequences as well as real effects, and their benefits are unequally distributed.
- 6 June 2024
- Published by Oxford University Press (OUP) in The Review of Financial Studies
- Vol. 37 (9) , 2817-2854
Financial Effects of Remote Product Delivery: Evidence from Hospitals
We study financial effects of remote product delivery in the healthcare industry. Exploiting staggered law adoption for identification, we find that telehealth provision redistributes hospital operations and access to capital away from rural communities. As urban telehealth providers acquire rural patients, rural hospitals experience decreased revenue and profit, credit rating downgrades, increased cost of capital, and ultimately risk of closure. Although telehealth reduces travel costs, some communities lose access to acute care. Overall, we conclude that remote healthcare services have financial consequences as well as real effects, and their benefits are unequally distributed.
- 13 January 2023
- Published by Elsevier in Journal of Financial Economics
- Vol. 147 (3) , 475-497
Common ownership and innovation efficiency
- 13 January 2023
- Published by Elsevier in Journal of Financial Economics
- Vol. 147 (3) , 475-497
Common ownership and innovation efficiency
- 1 September 2022
- Published by Institute for Operations Research and the Management Sciences (INFORMS) in Management Science
- Vol. 68 (9) , 6552-6571
Find and Replace: R&D Investment Following the Erosion of Existing Products
How do innovative firms react when existing products experience negative shocks? We explore this question with detailed project-level data from drug development firms. Using the Food and Drug Administration public health advisories as idiosyncratic negative shocks to approved drugs, we examine how drug makers react through investment decisions. Following these shocks, affected firms increase research and development (R&D) expenditures, driven by a higher likelihood of acquiring external innovations rather than developing novel projects internally. Such acquisition activities are concentrated in firms with weak research pipelines. We also find that competing developers move resources away from the affected therapeutic areas. Our results show how investments in specialized commercialization capital create path dependencies and alter the direction of R&D investments. This paper was accepted by Ashish Arora, entrepreneurship and innovation.
- 1 September 2022
- Published by Institute for Operations Research and the Management Sciences (INFORMS) in Management Science
- Vol. 68 (9) , 6552-6571
Find and Replace: R&D Investment Following the Erosion of Existing Products
How do innovative firms react when existing products experience negative shocks? We explore this question with detailed project-level data from drug development firms. Using the Food and Drug Administration public health advisories as idiosyncratic negative shocks to approved drugs, we examine how drug makers react through investment decisions. Following these shocks, affected firms increase research and development (R&D) expenditures, driven by a higher likelihood of acquiring external innovations rather than developing novel projects internally. Such acquisition activities are concentrated in firms with weak research pipelines. We also find that competing developers move resources away from the affected therapeutic areas. Our results show how investments in specialized commercialization capital create path dependencies and alter the direction of R&D investments. This paper was accepted by Ashish Arora, entrepreneurship and innovation.